EP0370994B1 - Traitement de liaisons transversales du collagène, initiées par le glucose chez les diabétiques, par l'arginine, la spermidine, la créatine ou l'agmatine - Google Patents

Traitement de liaisons transversales du collagène, initiées par le glucose chez les diabétiques, par l'arginine, la spermidine, la créatine ou l'agmatine Download PDF

Info

Publication number
EP0370994B1
EP0370994B1 EP89890116A EP89890116A EP0370994B1 EP 0370994 B1 EP0370994 B1 EP 0370994B1 EP 89890116 A EP89890116 A EP 89890116A EP 89890116 A EP89890116 A EP 89890116A EP 0370994 B1 EP0370994 B1 EP 0370994B1
Authority
EP
European Patent Office
Prior art keywords
collagen
arginine
glucose
cross
linking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP89890116A
Other languages
German (de)
English (en)
Other versions
EP0370994A2 (fr
EP0370994A3 (en
Inventor
Gert Prof. Dr. Lubec
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT290388A external-priority patent/AT393080B/de
Priority claimed from AT49889A external-priority patent/AT393079B/de
Application filed by Individual filed Critical Individual
Priority to US07/367,474 priority Critical patent/US5077313A/en
Publication of EP0370994A2 publication Critical patent/EP0370994A2/fr
Publication of EP0370994A3 publication Critical patent/EP0370994A3/de
Application granted granted Critical
Publication of EP0370994B1 publication Critical patent/EP0370994B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to the use of certain active ingredients for the manufacture of a medicament for the inhibition of pathological cross-linking of collagen in diabetes mellitus patients triggered by glucose.
  • Glucose reacts with amino groups of proteins in a reversible, nucleophilic addition reaction to form a Schiff's base adduct (aldimine), which is then converted into the more stable, yet reactive Amadori product in an Amadori rearrangement (cf. HB Mortensen and C Christophersen, Clin. Chim. Acta 134, 317 (1983)).
  • the resulting Amadori product then undergoes a number of other slow reactions with amino groups of other proteins to form glucose-derived intermolecular cross-links, such as the recently described advanced glycosylation product, namely 2- (2-furoyl) -4 (5) - (2-furanyl) -1H-imidazole (S. Pongor, PC Ulrich. FA Bencsath, A. Cerami, Proc. Natl.Acad. Sci USA, 81, 2684 (1984)).
  • aminoguanidine The in vivo effect of aminoguanidine has been demonstrated in non-diabetic and alloxan-diabetic rats. Intraperitoneal injections of aminoguanidine were given daily. The amount of fluorescent, advanced, non-enzymatic glycosylation products formed was determined. The degree of cross-linking of the aortic connective tissue was lower in aminoguanidine animals than in those who did not receive aminoguanidine.
  • aminoguanidine is extremely toxic. It can therefore not be used in practice.
  • arginine in medicine is already known, namely in the treatment of arginino-succinase deficiency, asthenospermia and immunomodulation.
  • the object of the invention is to provide substances which prevent the formation of cross-links in collagen proteins in a mode of action comparable to that of aminoguanidine and which are not toxic.
  • the invention proposes the use of arginine, in particular L (+) - arginine (HCOOC-CH (NH2) - (CH2) 3-NH-C (NH) -NH2), agmatine, the decarboxylation product of arginine (CH2 (NH2) - (CH2) 3-NH-C (NH) -NH2), creatine (N-amidinosarcosine, H2N-C (NH) -N (CH3) -CH2-COOH) or spermidine (N- (3-aminopropyl) -1.4- butanediamine, H2N- (CH2) 3-NH- (CH2) 4-NH2) or a salt thereof for the manufacture of a medicament for the inhibition of pathological cross-linking in collagen in diabetes mellitus patients.
  • an analog of arginine namely canavanine (HN (NH2) C-NH-O-CH2-CH2-CH (NH2) -COOH, can also be used.
  • Arginine is an amino acid that is non-toxic and is found in all proteins in daily food. Spermidine and creatine occur in significant quantities in the human organism.
  • the daily oral dose was 50 mg / kg body weight over a period of 5 weeks.
  • arginine for other purposes, e.g. for healthy diet supplements, and for diseases such as argininosuccinase deficiency, asthenospermia and immunomodulation.
  • arginine is commercially available e.g. in pharmacies, available without a prescription and has already been approved by the FDA as a dietary supplement in the United States.
  • the reaction mechanism for collagen protein in its glycosylated form with arginine is shown in the reaction scheme on the right, whereby arginine can react with one of its reactive, asterisked sites with the active carbonyl group of the ketoamine.
  • the reaction mechanism when using spermidine, creatine and agmatine corresponds to the mechanism shown in the reaction scheme for arginine.
  • arginine spermidine, creatine and agmatine
  • a pharmaceutically acceptable salt thereof e.g. Glutamate
  • an analogue thereof e.g canavanine as an analogue of arginine
  • the tests carried out on KK mice were carried out on spontaneously diabetic db / db mice from Great Britain. The same correlating results were obtained in this system as in the KK mice. This system is also a suitable model for type II diabetes.
  • the vessel (glomerular) basement membrane thicknesses were evaluated morphometrically and the mesangium proliferation was measured, and animals treated with L-arginine were compared with untreated control animals.
  • FIG. 1 shows an electron micrograph of a glomerulum without arginine treatment in a KK mouse.
  • Fig. 2 shows the same magnification of a glomerulum of a KK mouse treated with arginine.
  • FIG. 1 shows a thicker basement membrane compared to FIG. 2 and less proliferation in the mesangium. No mesangium proliferation and a thinner GMB (glomerular basement membrane) can be seen in FIG.
  • the animal models used in the experiments represent the treatment options for type I and type II diabetes.
  • Suitable pharmaceutical preparations for inhibiting the crosslinking of collagen are advantageously and in a simple manner by combining arginine, spermidine, creatine, agmatine, a salt or an analogue thereof with pharmaceutically suitable, chemically inert fillers, carriers, extenders and excipients, as are generally known Manufacture of drugs that are administered orally or parenterally, or that are to be injected locally, and that are collectively and collectively referred to in this specification and in the claims as "drug excipient".
  • the compounds according to the invention can be compounded or formulated in the form of tablets, powders, capsules, suspensions, solutions, emulsions and similar dosage forms.
  • the preparations can be prepared by mixing arginine, spermidine, agmatine, creatine, an analogue or a salt thereof, preferably in water-soluble form, with these customary diluents or tabletting additives, such as cellulose powder, corn starch, lactose, talc, stearic acid, magnesium stearate, gums or the like, according to the usual manufacturing methods known in the art getting produced.
  • the agents according to the invention can preferably be combined in their non-toxic, water-soluble form with carriers, such as water, saline solution, glucose solution or the like.
  • Effective amounts of any of the compounds used according to the invention can be administered to the body of a diabetic patient by one of various methods, for example orally, such as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, intravenously in sterile solution or locally in the form of sterile Solutions or suspensions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Claims (2)

  1. Utilisation de l'arginine, ou de ses analogues que sont la canavanine, la spermidine, la créatine et l'agmatine, ou d'un sel de ces composés, pour la préparation d'un médicament destiné à empêcher la réticulation pathologique du collagène chez les patients atteints de diabète sucré.
  2. Utilisation, selon la revendication 1, de la L(+)-arginine ou de l'un de ses sels.
EP89890116A 1988-11-25 1989-04-20 Traitement de liaisons transversales du collagène, initiées par le glucose chez les diabétiques, par l'arginine, la spermidine, la créatine ou l'agmatine Expired - Lifetime EP0370994B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/367,474 US5077313A (en) 1988-11-25 1989-06-16 Process for inhibiting pathological collagen cross-linking in diabetes patients

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT2903/88 1988-11-25
AT290388A AT393080B (de) 1988-11-25 1988-11-25 Pharmazeutische verwendung von arginin (salzen)
AT49889A AT393079B (de) 1989-03-06 1989-03-06 Pharmazeutische verwendung von agmatin
AT498/89 1989-03-06

Publications (3)

Publication Number Publication Date
EP0370994A2 EP0370994A2 (fr) 1990-05-30
EP0370994A3 EP0370994A3 (en) 1990-12-27
EP0370994B1 true EP0370994B1 (fr) 1992-12-23

Family

ID=25592942

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89890116A Expired - Lifetime EP0370994B1 (fr) 1988-11-25 1989-04-20 Traitement de liaisons transversales du collagène, initiées par le glucose chez les diabétiques, par l'arginine, la spermidine, la créatine ou l'agmatine

Country Status (4)

Country Link
EP (1) EP0370994B1 (fr)
JP (1) JPH02145514A (fr)
AT (1) ATE83658T1 (fr)
DE (1) DE58903113D1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1738762A1 (fr) * 2004-03-26 2007-01-03 Ajinomoto Co., Inc. Prevention/remede des complications du diabete a l'aide d'oligopeptide

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100919A (en) * 1984-03-19 1992-03-31 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
US5130324A (en) * 1984-03-19 1992-07-14 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US5468777A (en) * 1984-03-19 1995-11-21 The Rockefeller University Method and agents for preventing and reversing the staining of teeth
US5045469A (en) * 1988-10-27 1991-09-03 Mycogen Corporation Novel bacillus thuringiensis isolate denoted B. T. PS81F, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin
EP0599397B1 (fr) * 1992-11-17 1996-08-28 The Research Foundation Of State University Of New York Tétracyclines comprenant les tétracyclines modifiées chimiquement afin d'être non-antimicrobiennes inhibent la réticulation excessive du collagène lors du diabète
WO1994016687A1 (fr) * 1993-01-28 1994-08-04 The Trustees Of The University Of Pennsylvania Utilisation de la creatine ou d'analogues de la creatine pour la preparation d'un medicament qui empeche la croissance des tumeurs
AU5890394A (en) * 1993-02-03 1994-08-29 Steven Andrew Jennings Blends of glycine derivatives and sugars
AU692237B2 (en) * 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
JP3542665B2 (ja) * 1995-07-07 2004-07-14 株式会社資生堂 抗老化皮膚外用剤、コラーゲン架橋阻害皮膚外用剤及び抗紫外線皮膚外用剤
US6274161B1 (en) * 1996-05-31 2001-08-14 The Howard Foundation Compositions containing creatine in suspension
FR2802817B1 (fr) * 1999-12-23 2002-10-11 Centre Nat Rech Scient Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552179A (en) * 1976-11-02 1979-09-12 Beecham Group Ltd Pharmaceutical compositions for treating hyperglycaemia
US4758583A (en) * 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Merck Index, 10th Ed., 1983, p. 1251, 368, 169 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1738762A1 (fr) * 2004-03-26 2007-01-03 Ajinomoto Co., Inc. Prevention/remede des complications du diabete a l'aide d'oligopeptide
EP1738762A4 (fr) * 2004-03-26 2009-07-08 Ajinomoto Kk Prevention/remede des complications du diabete a l'aide d'oligopeptide

Also Published As

Publication number Publication date
JPH02145514A (ja) 1990-06-05
DE58903113D1 (de) 1993-02-04
EP0370994A2 (fr) 1990-05-30
EP0370994A3 (en) 1990-12-27
ATE83658T1 (de) 1993-01-15

Similar Documents

Publication Publication Date Title
DE69533940T2 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
DE3249683C2 (de) Verfahren zur Herstellung eines Verbundstoffs mit Langzeit-Freigabe
DE69034206T2 (de) Argininantagonisten zur Hemmung des systemischen Blutdruckes in Zusammenhang mitStickoxidbildung oder Endothelial Derived Relaxing Factor
DE69909794T2 (de) Verwendung eines dipeptids für wiederherstellungsprozesse
DE60212693T2 (de) Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie
EP0370994B1 (fr) Traitement de liaisons transversales du collagène, initiées par le glucose chez les diabétiques, par l'arginine, la spermidine, la créatine ou l'agmatine
US5077313A (en) Process for inhibiting pathological collagen cross-linking in diabetes patients
DE2260189A1 (de) Injizierbare aminosaeurepraeparate
DE2921312A1 (de) Pharmazeutisches mittel und dessen verwendung bei einer vollstaendig parenteralen ernaehrung
DE3115080A1 (de) Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung
DE602004005455T2 (de) Verfahren zur behandlung oder prävention von chronischen wunden und komplette nahrungszusammensetzung mit glycin und/oder leucin zur verwendung darin
DE3643119A1 (de) Therapeutische zusammensetzung fuer diabetes-komplikationen
DE69832165T2 (de) Hgf zur behandlung von akutem nierenversagen
DE69733207T2 (de) Verfahren zur hemmung von elf5a-biosynthese
EP0234186B1 (fr) Utilisation d'oligopeptides pour le traitement de désordres cérébraux
EP0199811B1 (fr) Medicament contenant des solutions d'acides amines pour le traitement de maladies cancereuses et son procede de preparation
EP1283047B1 (fr) Procede de production d'une substance biologiquement active a partir du serum sanguin
DE2709506A1 (de) Arzneimittel, enthaltend 10-deazaminopterin
DE69533742T2 (de) Verwendung von Prolin und/oder Derivaten als Mittel gegen Hepatitis
DE2455203C2 (fr)
DE2743704C2 (de) L- oder DL-Phenylglycine enthaltende Arzneimittel
AT393079B (de) Pharmazeutische verwendung von agmatin
DE3943424A1 (de) Infusions- und injektionsloesung zur intravenoesen verabreichung
DE1768655B2 (fr)
EP2747756B1 (fr) Sels métabolisables et leur utilisation pour le diagnostic et la thérapie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19910323

17Q First examination report despatched

Effective date: 19910930

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 19921223

Ref country code: BE

Effective date: 19921223

Ref country code: NL

Effective date: 19921223

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19921223

Ref country code: SE

Effective date: 19921223

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19921223

Ref country code: FR

Effective date: 19921223

Ref country code: GB

Effective date: 19921223

REF Corresponds to:

Ref document number: 83658

Country of ref document: AT

Date of ref document: 19930115

Kind code of ref document: T

REF Corresponds to:

Ref document number: 58903113

Country of ref document: DE

Date of ref document: 19930204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19930420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19930430

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19930430

Ref country code: LI

Effective date: 19930430

EN Fr: translation not filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
GBV Gb: ep patent (uk) treated as always having been void in accordance with gb section 77(7)/1977 [no translation filed]

Effective date: 19921223

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19940101